Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Johnson and Johnson
Citi
UBS
Mallinckrodt
Cipla
Harvard Business School
Argus Health

Generated: April 23, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NUCYNTA ER

« Back to Dashboard

Clinical Trials for NUCYNTA ER

Trial ID Title Status Sponsor Phase Summary
NCT00472303 A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). *Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.
NCT00472303 A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine Completed Grünenthal GmbH Phase 3 The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo. In addition tapentadol (CG5503) will also be compared to morphine controlled release, also referred to as slow release (SR). *Tapentadol prolonged-release (PR) is the term used in the European Union and is referred to as extended release (ER) in the United States.
NCT00505414 A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine Terminated Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 3 The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
NCT00505414 A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine Terminated Grünenthal GmbH Phase 3 The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for NUCYNTA ER

Condition Name

Condition Name for NUCYNTA ER
Intervention Trials
Pain 3
Back Pain 2
Low Back Pain 2
Chronic Pain 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for NUCYNTA ER
Intervention Trials
Chronic Pain 2
Low Back Pain 2
Back Pain 2
Osteoarthritis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for NUCYNTA ER

Trials by Country

Trials by Country for NUCYNTA ER
Location Trials
United States 33
Germany 4
Spain 4
Argentina 4
Poland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for NUCYNTA ER
Location Trials
Indiana 2
Ohio 2
North Carolina 2
New York 2
Louisiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for NUCYNTA ER

Clinical Trial Phase

Clinical Trial Phase for NUCYNTA ER
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for NUCYNTA ER
Clinical Trial Phase Trials
Completed 4
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for NUCYNTA ER

Sponsor Name

Sponsor Name for NUCYNTA ER
Sponsor Trials
Grünenthal GmbH 6
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2
Ortho-McNeil Janssen Scientific Affairs, LLC 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for NUCYNTA ER
Sponsor Trials
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Express Scripts
Merck
US Department of Justice
Argus Health
Queensland Health
Chinese Patent Office
Healthtrust
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.